摘要
Abstract
Objective To study the clinical effect of recombinant human interferon o2b (rhIFN-α2b) combined with Jieyoushen on cervical HPV infection,telomerase and expression of HPV16/18 E6 protein.Methods A total of 108 patients with cervical HPV infection who were treated in the First People's Hospital of Changzhou from January 2015 to January 2016 were selected.They were divided into observation group (54 cases) and control group (54 cases) according to the random number table method.The patients of the control group were treated with rhIFN-α2b,and the patients of the observation group were treated with rhIFN-α2b plus Jieyoushen.The efficacy and clinical indexes of the two groups were measured,and telomerase and HPV16/18 E6 protein expression were detected.Results The effective rate of the observation group was significantly higher than that of the control group (100.00％ vs.90.74％,P ＜ 0.05).The cure time,vaginal excretion time and bleeding time [(7.04 ± 1.68) w,(10.43± 1.93) d and (12.47 ± 1.56) d respectively] of the observation group were significantly shorter than those of the control group [(8.93 ± 2.45) w,(14.58 ± 2.76) d and (16.93 ± 3.88) d;P ＜ 0.05].After treatment,the load of HPV DNA in the observation group was significantly lower than that in the control group,and the conversion rate was significantly higher than that in the control group (94.44％ vs.74.07％,P ＜ 0.05).After treatment,the positive rates of telomerase and HPV16/18 E6 protein were significantly decreased in both groups,the positive rates of telomerase and HPV16/18 E6 protein in the observation group were significantly lower than those in the control group (1.85％ vs.11.11％,3.70％ vs.14.81％ respectively;P ＜ 0.05).Conclusions Combined use of rhIFN-αt2b and Jieyoushen has good therapeutic effect in the treatment of persistent HPV infection of cervix,can effectively reduce the positive rates of telomerase and HPV16/18 E6 protein,and reduce the risk of cervical cancer.关键词
重组人干扰素α2b/宫颈癌/宫颈持续HPV感染/端粒酶/HPV16/HPV18/HPVE6Key words
recombinant human interferon α2b/cervical cancer/cervical persistent HPV infection/telomerase/HPV16/HPV18/HPV E6分类
医药卫生
